The raise is an extension of a $27 million Series B round in early 2014 to prepare for the launch of several liquid biopsy cancer tests this year.
The tests are based on the company's ICE COLD PCR technology, which preferentially enriches mutant DNA sequences in an excess of wild-type DNA.
The Munich-based firm will use the funds to bring its Pharos400 laser-based PCR molecular diagnostic platform to market.
A new study has found that an antigen-based rapid diagnostic test for Ebola could be more reliable under certain circumstances than a recently approved RT-PCR assay for the virus.
Money from the private placement will be used for general corporate and working capital purposes, including activities supporting its ICE COLD-PCR technology.
In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.
US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.
Two research teams in China home in on a gene that gives rice a long, slender shape.
Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.
This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.